274 related articles for article (PubMed ID: 33276788)
21. Skin pigmentation and its control: From ultraviolet radiation to stem cells.
Yardman-Frank JM; Fisher DE
Exp Dermatol; 2021 Apr; 30(4):560-571. PubMed ID: 33320376
[TBL] [Abstract][Full Text] [Related]
22. SPRED1 deletion confers resistance to MAPK inhibition in melanoma.
Ablain J; Liu S; Moriceau G; Lo RS; Zon LI
J Exp Med; 2021 Mar; 218(3):. PubMed ID: 33306107
[TBL] [Abstract][Full Text] [Related]
23. Combined BRAF, MEK, and CDK4/6 Inhibition Depletes Intratumoral Immune-Potentiating Myeloid Populations in Melanoma.
Lelliott EJ; Mangiola S; Ramsbottom KM; Zethoven M; Lim L; Lau PKH; Oliver AJ; Martelotto LG; Kirby L; Martin C; Patel RP; Slater A; Cullinane C; Papenfuss AT; Haynes NM; McArthur GA; Oliaro J; Sheppard KE
Cancer Immunol Res; 2021 Feb; 9(2):136-146. PubMed ID: 33303574
[TBL] [Abstract][Full Text] [Related]
24. Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - A systematic review and meta-analysis.
Hussaini S; Chehade R; Boldt RG; Raphael J; Blanchette P; Maleki Vareki S; Fernandes R
Cancer Treat Rev; 2021 Jan; 92():102134. PubMed ID: 33302134
[TBL] [Abstract][Full Text] [Related]
25. Classification and Grading of Melanocytic Lesions in a Mouse Model of
Assenmacher CA; Santagostino SF; Oyama MA; Marine JC; Bonvin E; Radaelli E
J Histochem Cytochem; 2021 Mar; 69(3):203-218. PubMed ID: 33283624
[TBL] [Abstract][Full Text] [Related]
26. ITGBL1 is a new immunomodulator that favors development of melanoma tumors by inhibiting natural killer cells cytotoxicity.
Cheli Y; Tulic MK; El Hachem N; Nottet N; Jacquel A; Gesson M; Strub T; Bille K; Picard-Gauci A; Montaudié H; Beranger GE; Passeron T; Close P; Bertolotto C; Ballotti R
Mol Cancer; 2021 Jan; 20(1):12. PubMed ID: 33413419
[TBL] [Abstract][Full Text] [Related]
27. Melanoma models for the next generation of therapies.
Patton EE; Mueller KL; Adams DJ; Anandasabapathy N; Aplin AE; Bertolotto C; Bosenberg M; Ceol CJ; Burd CE; Chi P; Herlyn M; Holmen SL; Karreth FA; Kaufman CK; Khan S; Kobold S; Leucci E; Levy C; Lombard DB; Lund AW; Marie KL; Marine JC; Marais R; McMahon M; Robles-Espinoza CD; Ronai ZA; Samuels Y; Soengas MS; Villanueva J; Weeraratna AT; White RM; Yeh I; Zhu J; Zon LI; Hurlbert MS; Merlino G
Cancer Cell; 2021 May; 39(5):610-631. PubMed ID: 33545064
[TBL] [Abstract][Full Text] [Related]
28. The role of m
Nombela P; Miguel-López B; Blanco S
Mol Cancer; 2021 Jan; 20(1):18. PubMed ID: 33461542
[TBL] [Abstract][Full Text] [Related]
29. Immune Checkpoint Inhibitors in Advanced Acral Melanoma: A Systematic Review.
Zheng Q; Li J; Zhang H; Wang Y; Zhang S
Front Oncol; 2020; 10():602705. PubMed ID: 33344255
[TBL] [Abstract][Full Text] [Related]
30. Characterization of TERT and BRAF copy number variation in papillary thyroid carcinoma: An analysis of the cancer genome atlas study.
McKelvey BA; Zeiger MA; Umbricht CB
Genes Chromosomes Cancer; 2021 Jun; 60(6):403-409. PubMed ID: 33305870
[TBL] [Abstract][Full Text] [Related]
31. Human TYRP1: Two functions for a single gene?
Gautron A; Migault M; Bachelot L; Corre S; Galibert MD; Gilot D
Pigment Cell Melanoma Res; 2021 Sep; 34(5):836-852. PubMed ID: 33305505
[TBL] [Abstract][Full Text] [Related]
32. Increased rates of immunosuppressive treatment and hospitalization after checkpoint inhibitor therapy in cancer patients with autoimmune disease.
Bender DA; Heilbroner SP; Wang TJC; Shu CA; Hyde B; Spina C; Cheng SK
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33303578
[TBL] [Abstract][Full Text] [Related]
33. Genetic deciphering of the antagonistic activities of the melanin-concentrating hormone and melanocortin pathways in skin pigmentation.
Madelaine R; Ngo KJ; Skariah G; Mourrain P
PLoS Genet; 2020 Dec; 16(12):e1009244. PubMed ID: 33301440
[TBL] [Abstract][Full Text] [Related]
34. Different pathologic responses to neoadjuvant anti-PD-1 in primary squamous lung cancer and regional lymph nodes.
Ling Y; Li N; Li L; Guo C; Wei J; Yuan P; Tan F; Tao X; Wang S; Wang Z; Wu N; Wang J; Ying J; Gao S; He J
NPJ Precis Oncol; 2020 Dec; 4(1):32. PubMed ID: 33299121
[TBL] [Abstract][Full Text] [Related]
35. Identification of an RNA binding protein-related gene signature in hepatocellular carcinoma patients.
Wang L; Zhou N; Qu J; Jiang M; Zhang X
Mol Med; 2020 Dec; 26(1):125. PubMed ID: 33297932
[TBL] [Abstract][Full Text] [Related]
36. Immune Checkpoint Inhibitor with or without Radiotherapy in Melanoma Patients with Brain Metastases: A Systematic Review and Meta-Analysis.
Kim PH; Suh CH; Kim HS; Kim KW; Kim DY; Lee EQ; Aizer AA; Guenette JP; Huang RY
Korean J Radiol; 2021 Apr; 22(4):584-595. PubMed ID: 33289357
[TBL] [Abstract][Full Text] [Related]
37. Making a melanoma: Molecular and cellular changes underlying melanoma initiation.
Darp R; Ceol C
Pigment Cell Melanoma Res; 2021 Mar; 34(2):280-287. PubMed ID: 33283422
[TBL] [Abstract][Full Text] [Related]
38. Characterization of novel neutralizing mouse monoclonal antibody JM1-24-3 developed against MUC18 in metastatic melanoma.
Feng R; Wang Y; Ramachandran V; Ma Q; May MM; Li M; Zhou JX; Xu X; Xu K; Fang S; Xia W; Sui D; Liu H; Gao X; Prieto V; Blacklow SC; Lu M; Lee JE
J Exp Clin Cancer Res; 2020 Dec; 39(1):273. PubMed ID: 33278894
[TBL] [Abstract][Full Text] [Related]
39. EZH2 is a potential prognostic predictor of glioma.
Chen YN; Hou SQ; Jiang R; Sun JL; Cheng CD; Qian ZR
J Cell Mol Med; 2021 Jan; 25(2):925-936. PubMed ID: 33277782
[TBL] [Abstract][Full Text] [Related]
40. Understanding the tumor microenvironment for effective immunotherapy.
Sadeghi Rad H; Monkman J; Warkiani ME; Ladwa R; O'Byrne K; Rezaei N; Kulasinghe A
Med Res Rev; 2021 May; 41(3):1474-1498. PubMed ID: 33277742
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
